Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resistance and tumor recurrence. Therefore, understandin...

Full description

Bibliographic Details
Main Authors: Jason T Fong, Ryan J Jacobs, David N Moravec, Srijayaprakash B Uppada, Gregory M Botting, Marie Nlend, Neelu Puri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3817236?pdf=render

Internet

http://europepmc.org/articles/PMC3817236?pdf=render

Similar Items